Navigation

Adphen

Adphen - General Information

Adphen is a weight loss medication. Adphen is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.

 

Pharmacology of Adphen

Adphen is a phenylalkylamine sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance has been demonstrated with all drugs of this class in which these phenomena have been looked for. Drugs of this class used in obesity are commonly known as ''anorectics or anorexigenics." It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions or metabolic effects, may be involved.

 

Adphen for patients

 

Adphen Interactions

 

Adphen Contraindications

Known hypersensitivity or idiosyncratic reactions to sympathomimetics. Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and severe hypertension, hyperthyroidism, glaucoma.

Highly nervous or agitated patients. Patients with a history of drug abuse. Patients taking other CNS stimulants, including monamine oxidase inhibitors.

 

Additional information about Adphen

Adphen Indication: Used in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.
Mechanism Of Action: Not Available
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Phendimetrazine
Synonyms: (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-phendimetrazine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3-Phenyl-2-methylmorpholine; d-2-Phenyl-3,4-dimethylmorpholine
Drug Category: Anorexigenic Agents
Drug Type: Small Molecule; Illicit; Approved
Other Brand Names containing Phendimetrazine: Adphen; Antapentan; Bacarate; Bontril; Dyrexan; Hyrex; Mephenmetrazine; Sedafamen; Wehless; X-trozine; Prelu-2;
Absorption: Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours.
Toxicity (Overdose): Acute overdosage of phendimetrazine may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerance, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma and death.
Protein Binding: Not Available
Biotransformation: Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction
Half Life: 19-24 hours
Dosage Forms of Adphen: Tablet Oral
Chemical IUPAC Name: 3,4-dimethyl-2-phenylmorpholine
Chemical Formula: C12H17NO
Phendimetrazine on Wikipedia: http://en.wikipedia.org/wiki/Phendimetrazine
Organisms Affected: Humans and other mammals